Well, it didn’t take long for Sanofi to follow Eli Lilly and Novo Nordisk to cut its insulin prices. Yesterday it announced starting next year, Lantus, its most popular insulin will.come down 78%, with a monthly cap of $35 for people with private insurance.

It’s also lowering the price of its short-acting insulin, Apridra, 70%.

Sanofi already has in place a $35 monthly cap for uninsured people with diabetes.

These three companies control over 90% of the global insulin market, and finally, with the threat of government pressure, they’re lowering their inflated prices that have tripled over the past decade. It still amazes me each of the CEO’s say we’re doing it because it’s time. Really? Seems like it’s been time for a very long time.

For more details, click here.